Effect of induction therapy on outcome by postremission therapies
| Consolidation arm . | 5-year OS . | 5-year RFS . | ||
|---|---|---|---|---|
| IDR group . | DNR group . | IDR group . | DNR group . | |
| Conventional standard-dose, % | 57 | 56 | 41 | 37 |
| P | .759 | .332 | ||
| High-dose Ara-C, % | 58 | 58 | 42 | 44 |
| P | .725 | .658 | ||
| Allogeneic SCT in first CR, % | 59 | 59 | 58 | 64 |
| P | .469 | .394 | ||
| Consolidation arm . | 5-year OS . | 5-year RFS . | ||
|---|---|---|---|---|
| IDR group . | DNR group . | IDR group . | DNR group . | |
| Conventional standard-dose, % | 57 | 56 | 41 | 37 |
| P | .759 | .332 | ||
| High-dose Ara-C, % | 58 | 58 | 42 | 44 |
| P | .725 | .658 | ||
| Allogeneic SCT in first CR, % | 59 | 59 | 58 | 64 |
| P | .469 | .394 | ||
Number of patients in the conventional standard-dose arm was 196 in the IDR group and 196 in the DNR group; in the high-dose Ara-C arm, the numbers were 196 and 193, respectively; and in the SCT group, the numbers were 67 and 69, respectively, as shown in Figure 1.
OS indicates overall survival; RFS, relapse-free survival; IDR, idarubicin; DNR, daunorubicin; Ara-C, cytarabine; and CR, complete remission.